Valuation: Renalytix Ai PLC

Market Cap 1.33Cr 1.16Cr 1.09Cr 99.17L 1.86Cr 127.94Cr 1.87Cr 13Cr 5.04Cr 65Cr 5.01Cr 4.9Cr 206.84Cr P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 1.79Cr 1.55Cr 1.47Cr 1.33Cr 2.5Cr 172.06Cr 2.51Cr 18Cr 6.78Cr 87Cr 6.74Cr 6.59Cr 278.18Cr EV / Sales 2024
1,10,59,330x
EV / Sales 2025 1,24,99,418x
Free-Float
79.62%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 15/03/2018
Director of Finance/CFO 68 28/05/2024
President 65 30/04/2024
Director TitleAgeSince
Chairman 62 05/11/2024
Director/Board Member 58 15/03/2018
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+11.48%+33.33% - - 5.08Cr
+1.09%+6.50%+23.23%-27.12% 1.74TCr
-0.23%+10.16%-44.30%+53.83% 188.17Cr
+0.46%-1.79%-31.58%+20.06% 87Cr
0.00%-0.16%+58.81%-2.02% 78Cr
+1.32%-14.79%-63.53%-85.78% 74Cr
0.00%-5.30%-39.39%-51.20% 63Cr
+1.52%-4.78%-43.79%-54.61% 58Cr
+2.68%+4.03%-42.89%-37.76% 44Cr
-0.50%+2.37%+61.04%+55.97% 41Cr
Average +1.78%-1.33%-13.60%-14.29% 263.76Cr
Weighted average by Cap. +0.94%+1.51%+10.48%-20.05%

Financials

2024 2025
Net sales 2.29 1.98 1.87 1.7 3.19 219.59 3.21 22.38 8.65 111.38 8.6 8.41 355.01 3 2.6 2.46 2.23 4.18 287.8 4.21 29.33 11.34 145.97 11.27 11.02 465.28
Net income -3.35Cr -2.9Cr -2.74Cr -2.49Cr -4.66Cr -320.95Cr -4.69Cr -33Cr -13Cr -162.79Cr -13Cr -12Cr -518.88Cr -2.04Cr -1.77Cr -1.67Cr -1.52Cr -2.84Cr -195.7Cr -2.86Cr -20Cr -7.71Cr -99Cr -7.66Cr -7.49Cr -316.39Cr
Net Debt 38.55L 33.41L 31.58L 28.67L 53.73L 37Cr 54.05L 3.77Cr 1.46Cr 19Cr 1.45Cr 1.42Cr 60Cr 46L 39.86L 37.68L 34.21L 64.11L 44Cr 64.49L 4.5Cr 1.74Cr 22Cr 1.73Cr 1.69Cr 71Cr
Logo Renalytix Ai PLC
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!